News

The study is enrolling patients with non-small cell lung cancer (NSCLC) who have failed prior therapy.  The trial will begin with a Phase 1 safety component, enrolling up

TetraLogic sold its SMAC mimetic program, including their clinical stage asset birinapant, and their topical HDAC inhibitor, remetinostat (SHAPE), to Medivir for a purchase price of $12m payable in

Following a preliminary review of the company's NDA for Xaracoll, filed in October 2016, the FDA concluded that the application was not sufficiently complete to allow for a more

The REACH-1 phase 2 trial is assessing ruxolitinib in combination with corticosteroids It has a primary endpoint defined as overall response rate at day 28 of the single-cohort clinical trial. Some

The Pennsylvania based global pharma rolled out Methylphenidate Hydrochloride extended-release tablets USP, 18mg, 27mg, 36mg and 54mg, which are indicted for treatment of Attention Deficit Hyperactivity Disorder (ADHD).

The brands bought by Zydus Healthcare in the deal are Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten which are expected to strengthen the global pharmaceutical group’s portfolio in

Effi-7, an antagonist of the interleukin-7 receptor, is intended to treat patients suffering from invalidating autoimmune pathologies. The deal is inclusive of an upfront payment of €10.25m by

Kubota Pharmaceutical will hold 51% stake while the remainder will be held by SBI in the unnamed joint venture which will organize and manage special purpose entities in

As part of the deal, Pfizer has acquired the commercialisation and development rights of AstraZeneca’s approved antibiotics Merrem, Zinforo and Zavicefta as well as its ATM-AVI and CXL